Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03488953 |
Title为孤立、不可切除的结直肠肝转移患者进行活体肝移植和两期肝切除术 | 阶段
不适用
|
Date Added 2018-04-05 |
地点
德国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03476681 |
TitleNEO-201 在实体瘤中的研究扩增队列 | 阶段
Phase 1, Phase 2
|
Date Added 2018-03-26 |
地点
Maryland, United States
Virginia, United States |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
NEO-201 in combination with pembrolizumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03475004 |
TitleStudy of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer | 阶段
第二阶段
|
Date Added 2018-03-23 |
地点
Colorado, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Pembrolizumab, Bevacizumab, and Binimetinib |
标签
MSS/ MMRp
|
| NCT ID NCT03412877 |
Title对转移性癌症患者施用经基因工程改造可表达对新抗原有反应的 T 细胞受体的自体 T 细胞 | 阶段
第二阶段
|
Date Added 2018-01-29 |
地点
Maryland, United States
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
Aldesleukin, Cyclophosphamide, Fludarabine, Individual Patient TCR-Transduced PBL, Pembrolizumab (Keytruda) |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03400332 |
TitleBMS-986253与Nivolumab或Nivolumab加Ipilimumab联合治疗晚期癌症的研究 | 阶段
第二阶段
|
Date Added 2018-01-17 |
地点
Arkansas, United States
California, United States Colorado, United States Georgia, United States Maryland, United States Massachusetts, United States Michigan, United States Nebraska, United States Nevada, United States New Jersey, United States New York, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Texas, United States Utah, United States Virginia, United States 澳大利亚 比利时 加拿大 法国 德国 意大利 波兰 西班牙 瑞典 瑞士 英国 |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
BMS-986253, Ipilimumab, Nivolumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03388632 |
Title重组白细胞介素-15 与检查点抑制剂 Nivolumab 和 Ipilimumab 联合治疗难治性癌症患者 | 阶段
第 1 阶段
|
Date Added 2018-01-03 |
地点
Maryland, United States
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
Ipilimumab, Nivolumab, rhIL-15, Opdivo, Yervoy |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03388190 |
TitleMETIMMOX: Colorectal Cancer METastasis – Shaping Anti-tumor IMMunity by OXaliplatin | 阶段
第二阶段
|
Date Added 2018-01-02 |
地点
挪威
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
FLOX, Nivolumab, Opdivo |
标签
MSS/ MMRp
|
| NCT ID NCT03368963 |
TitleTAS102 与 NAL-IRI 联合治疗晚期消化道癌症 | 阶段
Phase 1, Phase 2
|
Date Added 2017-12-11 |
地点
Georgia, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03366155 |
Title肝动脉输注泵化疗与全身化疗联合应用于转移至肝脏的结直肠癌患者 | 阶段
第二阶段
|
Date Added 2017-12-08 |
地点
Maryland, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
5FU, cetuximab, FUDR-Dex, Irinotecan, Medtronic SynchroMed II Pump with Codman 3000 Constant Flow Pump Catheter, OneRNA, oxaliplatin, panitumumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03365882 |
TitleS1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery | 阶段
第二阶段
|
Date Added 2017-12-07 |
地点
Alaska, United States
Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Washington, United States West Virginia, United States Wisconsin, United States Wyoming, United States 波多黎各 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
cetuximab, HER-2 testing, Irinotecan Hydrochloride, Pertuzumab, Trastuzumab, Camptosar, Erbitux, Herceptin, Perjeta |
标签
MSS/ MMRp
|
